Francina Agosti on Muck Rack

Francina Agosti

Verified
(She/Her)
Genoa, Italy
As seen in: BrightFocus Foundation, European Biotechnology, Labiotech, Big Think, BioRxiv, EIN News, NewsBreak, The Journal of Clinical Investigation, Advanced Science News, Freethink, Drug Discovery News (DDN), Exosome RNA
Covers:  biotech, science, life science, clinical trials, research news
Divorced from academia, dating biotech writing, having an affair with science news🔭 When not writing, I'm walking my dog in the ⛰️ agfrancina@gmail.com 📩

Get in touch with Francina

Contact Francina, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Francina Agosti’s Biography

Read Full Bio →

Biotech and science freelance writer, former neuroscientist, forever nerd.

I enjoy translating complex scientific discoveries and medical data into engaging and understandable copy to educate the general public, scientists, and investors.

Articles

Why Customer Experience Centers are becoming practical infrastructure for life sciences innovation in Europe

|
By Francina Agosti Verified
| Labiotech Verified
Photo credits: MGI Tech Co., Ltd Newsletter Signup - Under Article / In Page "*" indicates required fields This field is for validation purposes and should be left unchanged.
Open in Who Shared View Duplicates (2) Issue with article?

Bionyra launches with $165m, France’s largest biotech Series A

|
By Francina Agosti Verified
| European Biotechnology Verified
The oversubscribed Series A of $165 million (~€143 million) was co-led by two strong VCs in the European biotech space, Sofinnova Partners (which, less than a year ago, also co-founded the company) and Jeito Capital. Other participants in the funding are Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Health Ventures.
Open in Who Shared Issue with article?

Bionyra launches with $165m, France’s largest biotech Series A

|
By Francina Agosti Verified
| EIN News
With an unusually strong fundraising trajectory, Paris-based Bionyra Pharma emerged from stealth today with financing that marks the largest life sciences biopharma Series A round in Europe this year and the largest of all time in France. The company develops next-generation biologics for immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD) and atopic dermatitis.
Open in Who Shared Issue with article?
See all 83 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified